Statins in the prevention of heart failure after myocardial infarction.

Current Heart Failure Reports
Helene Glassberg

Abstract

Statin therapy has demonstrated clear reductions in the risk of death and recurrent cardiac events in patients with acute coronary syndrome (ACS) and coronary artery disease. Heart failure after myocardial infarction (MI) is associated with increased in-hospital mortality and worse long-term prognosis. Some controversy exists about the effects of statin therapy on heart failure, although the favorable effects of statin therapy likely reduce the risk of heart failure development after MI and ACS. This article reviews data on statin therapy and the incidence of heart failure after MI, discussing mechanisms, safety, and outcomes.

References

Nov 24, 1999·Clinical and Experimental Pharmacology & Physiology·J D LuoX Chen
Oct 19, 2000·Lancet·M RauchhausS D Anker
May 22, 2002·Journal of the American College of Cardiology·Henry Krum, John J McMurray
Oct 25, 2002·Journal of Cardiac Failure·Tamara B HorwichGregg C Fonarow
Apr 16, 2003·Circulation·Rainer U PliquettIrving H Zucker
Dec 10, 2003·Journal of the American College of Cardiology·Mathias RauchhausStefan D Anker
Feb 21, 2004·Journal of the American College of Cardiology·Tamara B HorwichGregg C Fonarow
Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Jan 7, 2005·The New England Journal of Medicine·Paul M RidkerUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Inv
Mar 10, 2005·The New England Journal of Medicine·John C LaRosaUNKNOWN Treating to New Targets (TNT) Investigators
Jun 25, 2005·International Journal of Cardiology·R Scott WrightAllan S Jaffe
Nov 17, 2005·JAMA : the Journal of the American Medical Association·Terje R PedersenUNKNOWN Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group
Dec 13, 2005·Circulation Research·Yoshiyuki Rikitake, James K Liao
Mar 15, 2006·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN ASTEROID Investigators
Apr 18, 2006·The American Journal of Cardiology·Tomohiro SakamotoUNKNOWN Multicenter Study for Aggressive Lipid-Lowering Strategy by HMG-CoA Reductase Inhibitors in Patients With Acute Myocardial I
Jun 6, 2006·Journal of the American College of Cardiology·Benjamin M SciricaUNKNOWN PROVE IT-TIMI 22 Investigators
Jan 24, 2007·Journal of the American College of Cardiology·UNKNOWN Heart Protection Study Collaborative GroupRory Collins
Nov 7, 2007·The New England Journal of Medicine·John KjekshusUNKNOWN CORONA Group
Nov 7, 2007·The New England Journal of Medicine·Frederick A Masoudi
Nov 20, 2008·Journal of the American College of Cardiology·Sarah L MolyneuxA Mark Richards
Feb 4, 2010·Clinical Cardiology·Faramarz TehraniErnst R Schwarz

❮ Previous
Next ❯

Citations

Jun 28, 2011·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·A D Dergunov
Apr 5, 2013·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Waqas QureshiFatima Khalid

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.